Alteogen Signs $365 Million Licensing Deal for Subcutaneous Drug Delivery Platform ALT-B4
Biotechnology firm Alteogen has signed an exclusive technology-transfer agreement worth up to $365 million (approximately 521.
Search results for "Bio"
From Retinal Scans to Brain Imaging: South Korea Backs Six Medical AI Tools for Fast-Track Hospital Adoption
Medical AI tools designed to assess cardiovascular risk from retinal images and analyze brain scans for stroke severity are set to undergo...
CAR-T Without Extracting Patient Cells? J&J Makes $785 Million Bet on In Vivo Therapy
Johnson & Johnson (J&J) is investing more than $785 million (approximately 1.11 trillion won) in next-generation "in...
More Protein Than Greek Yogurt: 5 Diet-Friendly Foods to Upgrade Your Meal Rotation
Greek yogurt has become one of the most widely discussed high-protein foods in recent years.
AI Tracks Lung Scarring: 4-Percentage-Point Rise in One Year Signals Danger
Researchers have established an artificial intelligence benchmark to quantify the progression of idiopathic pulmonary...
White Frost on Ice Cream: Safe to Eat or Time to Toss?
On a hot summer day, a freezer stocked with ice cream is a welcome comfort. Many people, particularly when eating from...
"Can I Get TAVI, Too?": 11 Key Questions to Ask Before an Aortic Valve Procedure
Many patients with severe aortic valve stenosis delay treatment out of fear of open-heart surgery.
Scalp-Injected RNA Hair Loss Drug Completes Phase 1b Dosing in Australia
OliX announced on August 4 that it has completed patient dosing in the Australian Phase 1b clinical trial for OLX104C...
Antihistamines Provide Minimal Relief for Atopic Dermatitis Itch, Study Finds
Antihistamines commonly used to ease itching from atopic dermatitis do not deliver a large enough benefit for patients...
Daegu Broadens Anti-Aging Focus Beyond Skin to Whole-Body Health
The era of relying solely on cosmetic procedures to maintain youth is fading. Taking its place is "internal...